Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Peter Dumas

Gastroenterology Venice, FL Medical Doctor

NPI 1043245665 CMS profile 1659

825 Venetian Pkwy, Venice, FL 34285

Open in the dashboard

General payments

$8,162

415 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Peter Dumas of Venice, FL is reported in the CMS Open Payments database as having received $8,162 across 415 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $131 2
2023 General $2,344 119
2022 General $1,895 95
2021 General $1,238 69
2020 General $506 26
2019 General $2,048 104

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Dumas
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Peter Dumas were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Peter Dumas Gastroenterology median Middle half National median
2019 $2,048 $417 $126–$1,100 $163
2020 $506 $224 $74–$624 $114
2021 $1,238 $352 $106–$1,054 $132
2022 $1,895 $448 $129–$1,270 $149
2023 $2,344 $533 $150–$1,390 $160
2024 $131 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $3,028 170 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $811 45 payments
  3. Janssen Biotech, Inc. $698 35 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $607 34 payments
  5. Celgene Corporation $340 18 payments
  6. Pfizer Inc. $302 12 payments
  7. Ironwood Pharmaceuticals, Inc $208 10 payments
  8. Allergan Inc. $192 15 payments
  9. Genzyme Corporation $192 6 payments
  10. VIVUS, Inc. $191 10 payments
  11. Other $1,592 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $8,027 412 payments
  2. Education $116 2 payments
  3. Consulting Fee $19 1 payment
Products named General payments · program years 2019–2024
  1. XIFAXAN $756 42 payments
  2. RINVOQ $724 43 payments
  3. HUMIRA $705 33 payments
  4. STELARA $698 35 payments
  5. SKYRIZI $670 32 payments
  6. REMICADE $537 31 payments
  7. CREON $525 36 payments
  8. SIMPONI ARIA $511 29 payments
  9. SIMPONI $511 29 payments
  10. LINZESS $471 37 payments
  11. Other $4,226 205 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

331

Median for Internal Medicine: 777

Drug cost

$4,668

Median for Internal Medicine: $73,373

Branded share of claims

0%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pantoprazole Sodium Generic 161 $2,345
Omeprazole Generic 128 $1,728
Sucralfate Generic 18 $410
Famotidine Generic 24 $185

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Pharmaceuticals, Inc. $104
$104 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

415 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record